Cinvanti was Heron Therapeutics’s largest product and service line in fiscal 2025, bringing in $96.76M of $154.90M (62%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Cinvanti | $87.25M | $94.87M | $100.08M | $96.76M | ||||
| Zynrelef | $10.20M | $17.73M | $25.55M | $38.07M | ||||
| Sustol | $10.23M | $13.06M | $14.14M | $8.50M | ||||
| Aponvie | — | $1.39M | $4.52M | $11.57M | ||||
| Total | $107.67M | $127.04M | $144.29M | $154.90M |
Heron Therapeutics brought in $154.90M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 7.4% from $144.29M in fiscal 2024. Cinvanti was the largest at $96.76M (62.5%), ahead of Zynrelef at $38.07M (24.6%) and Aponvie at $11.57M (7.5%). The remaining line, Sustol, brought in $8.50M.
Compared with fiscal 2024, Aponvie grew fastest, up 156.1% to $11.57M, while Sustol fell the most, down 39.9% to $8.50M.
Heron Therapeutics began breaking out Aponvie in fiscal 2023, when it brought in $1.39M.
Heron Therapeutics (HRTX) reports its revenue by product and service. In fiscal 2025, Cinvanti was its largest product and service line, bringing in $96.76M (62.5% of the total), followed by Zynrelef at $38.07M (24.6%).
Cinvanti was Heron Therapeutics' largest product and service line in fiscal 2025, bringing in $96.76M, or 62.5% of the $154.90M total across its four product and service lines.
Among Heron Therapeutics' product and service lines that make up at least 2% of revenue, Aponvie grew fastest in fiscal 2025, up 156.1% from $4.52M to $11.57M.
Every figure comes from Heron Therapeutics' annual financial filings, as reported. Each line keeps the name Heron Therapeutics gives it, and years follow its fiscal calendar.
Heron Therapeutics' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.